This site is intended for healthcare professionals
Drug news

Interim analysis of MAGNIFY phase IIIb study of Revlimid (lenalidomide) plus rituximab in marginal zone lymphoma- Celgene Corp

Read time: 1 mins
Last updated:26th Jun 2017
Published:19th Jun 2017
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest